

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Disse, B.) Art Unit: 1614 U.S. Appln. No. : 10/644,333) Examiner: V. Y. KIM Confirmation No.: 6665 U.S. Filing Date : 08/20/2003 Title of Invention: Compounds For Treating Inflammatory Diseases Attny. Docket No.: 1/1196-1-C1 Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450 December 2, 2003 TRANSMITTAL LETTER FOR INFORMATION DISCLOSURE STATEMENT Sir: Transmitted herewith concerning the subject application is an Information Disclosure Statement (Form 1449A and B) with copies of all references cited therein. This is being submitted pursuant to 37 C.F.R. §1.56 and before the mailing of a first Office Action on the merits, pursuant to 37 CFR § 1.97(b). It should be noted that the references listed in the Information Disclosure Statement have been cited in the International Search Report (ISR) for PCT/EP 02/01986, which corresponds to the present US application. A copy of that ISR is enclosed herewith. \boxtimes 1.97(b). This Statement is being filed: i) within three (3) months of the filing date of a national application other than a continued prosecution application under 33 C.F.R. §1.53 (d); ii) within three (3) months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application; iii) before the mailing of a first Office action on the merits; or iv) before the mailing of a first Office action after the filing of a request for continued examination under 37 C.F.R. §1.114. 1.97(c). This Statement is being filed after the time period specified in 37 C.F.R. §1.97(b), but before the mailing date of: i) a final action under 37 C.F.R. §1.113, ii) a notice of allowance under 37 C.F.R. §1.311, or iii) an action that otherwise closes prosecution in the application. This Statement is being accompanied by:

A statement as specified in 37 C.F.R. §1.97(e) [see below]; or

		The fee set forth in 37 C.F.R. §1.17(p).
		The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.
	ent as s	This Statement is being filed after the period specified in 37 C.F.R. n or before payment of the issue fee. This Statement is accompanied by a pecified in 37 C.F.R. §1.97(e) [see below] and the fee set forth in 37 C.F.R.
	1.97(e)).
	counte	Each item of information contained in the instant information disclosure ent was first cited in any communication from a foreign patent office in a rpart foreign application not more than three (3) months prior to the filing of tant information disclosure statement; or
	foreign making inform C.F.R.	No item of information contained in the instant information disclosure ent was cited in a communication from a foreign patent office in a counterpart application, and, to the knowledge of the person signing this certification after greasonable inquiry, no item of information contained in the instant ation disclosure statement was known to any individual designated in 37 §1.56(c) more than three (3) months prior to the filing of the instant ation disclosure statement.
		The fee set forth in 37 C.F.R. §1.17(p).
		The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.
counte in sect	rpart ap	d). Each item of information contained in the accompanying information ement was cited in a communication from a foreign patent office in a plication, which communication was not received by any individual designated (c) more than thirty (30) days prior to the filing of the accompanying sclosure statement.

The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. §1.16 and any patent application processing fees under 37 C.F.R. §1.17, or credit any overpayment of same, to Deposit Account No. 02-2955.

Triplicate copies of this form are enclosed.

Respectfully submitted,

Michael P. Mories

Michael P. Morris Attorney for Applicant(s). Reg. No. 34,513

Certificate of Mailing

Michael P. Morris Michael P. Morris, Reg. No. 34,513

I hereby certify that this correspondence is being deposited

with the U.S. Postal Service with sufficient postage as first

Patent Department Boehringer Ingelheim Corp. 900 Ridgebury Road, P.O. Box 368 Ridgefield, CT 06877 Tel: (203) 798-5285

Date: December 2, 2003

Commissioner For Patents P. O. Box 1450

class mail in an envelope addressed to:

Alexandria, VA 22313-1450

on December 2, 2003.

PTO/SB/08a (06-03)

Approved for use through 07/31/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

 Complete if Known

 Application Number
 10/644,333

 Filing Date
 08/20/2003

 First Named Inventor
 Bernd DISSE

 Art Unit
 1614

 Examiner Name
 V. Y. Kim

 Attorney Docket Number
 1/1196-1-C1

(Use as many sheets as necessary)

Sheet 1 of 2 Attorney Docket Number 1/1196-1-C1

		_	U. S. PATENT D	OCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (f known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-		The second secon	
		US-			

	FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ :Number ⁴ :Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T _e
		WO 99 66944 A	12/29/1999	Adv. Medicine, Inc.		
••••••						
***************************************	************					

	 	_	
Examiner Signature	Date Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optionat). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (VVIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b (06-03) Approved for use through 06/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

titute for form 1449B/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

2

	Complete if Known	
Application Number	10/644,333	
Filing Date	08/20/2003	
First Named Inventor	Bernd DISSE	
Art Unit	1614	
Examiner Name	V. Y. Kim	
Attorney Docket Number	1/1196-1-C1	

NON PATENT LITERATURE DOCUMENTS						
Initials* No.1 magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publis and/or country where published.		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²			
		LITTNER, M. R. ET AL; "Long-Acting Bronchodilation with Once-Daily Dosing of Tiotropium (Spiriva) in Stable Chronic Obstructive Pulmonary Disease"; Am J Resp and Critical Care Med; Am Lung Assn,; 161(41) 2000; pgs 1136-1142; XP001148373				
		LASSERSON, T. ET AL; "Anticholinergic Therapy For Bronchiectasis"; Cochrane Database of Systematic Reviews; 4; 2001; XP008019810				
		ROGERS, D. F.; "Mucus pathophysiology in COPD: differences to asthma, and pharmacotherapy"; Monaldi Archives for Chest Disease, 55(4); 2000, pgs 324-332; XP008019816				
;•						
••••••						

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.